Approval of an immunotherapy for adjuvant NSCLC indication gives us new reasons for finding early-stage disease
Fred Hirsch, MD, PhD, discusses the approval of immunotherapy for adjuvant NSCLC indication that gives us new reasons for finding early-stage disease.
